First Tracks Biotherapeutics will discuss top-line data from its celiac disease trial of ANB033 on October 12, 2026.
Quiver AI Summary
First Tracks Biotherapeutics, Inc. will host an investor call and live webcast on October 12, 2026, at 8:30 AM ET to discuss top-line data from a gluten-challenge study assessing their investigational drug ANB033 in celiac disease. This study is part of a global Phase 1b trial aimed at preventing mucosal damage. The data will be released in a morning press release and presented during the webcast, which will also be available for replay for 30 days. First Tracks Biotherapeutics is focused on developing antibody therapeutics for autoimmune and inflammatory diseases, with a portfolio that includes ANB033 and other candidates in various stages of development.
Potential Positives
- First Tracks Biotherapeutics is set to share top-line data from a global Phase 1b trial of investigational ANB033, indicating ongoing research and development in the treatment of celiac disease.
- The company is engaging with investors through a live webcast, demonstrating transparency and commitment to informing stakeholders about progress in their clinical trials.
- The availability of a replay for the webcast ensures that broader audiences, including potential investors, can access and understand the company's advancements over an extended period.
Potential Negatives
- The press release lacks detailed results or insights from the trial, which could leave stakeholders uncertain about the efficacy of the investigational drug ANB033.
- The company is in the clinical stage, which generally implies higher risk and uncertainty regarding the successful development and commercialization of its therapies.
- There is no mention of any partnerships or collaborations that could support the advancement of its pipeline, potentially indicating a lack of strategic alliances.
FAQ
What is ANB033 and what condition does it target?
ANB033 is a CD122 antagonist being developed for the treatment of celiac disease and eosinophilic esophagitis.
When is First Tracks Biotherapeutics' investor call scheduled?
The investor call is scheduled for Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.
How can I access the live webcast of the investor call?
The live webcast can be accessed on the First Tracks website at https://ir.firsttracksbio.com/news-events/events.
Will there be a replay of the investor call available?
Yes, a replay of the webcast will be available for at least 30 days following the event.
Who can I contact for investor relations inquiries?
You can contact Nick Montemarano, Vice President, Investor Relations, at 858.732.0178 or [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TRAX Insider Trading Activity
$TRAX insiders have traded $TRAX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TRAX stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 sold 4,705,575 shares for an estimated $64,999,989
- J. ANTHONY WARE sold 39,265 shares for an estimated $1,758,145
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TRAX Hedge Fund Activity
We have seen 135 institutional investors add shares of $TRAX stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 3,174,519 shares (+inf%) to their portfolio in Q2 2026, for an estimated $63,871,322
- TCG CROSSOVER MANAGEMENT, LLC added 2,895,304 shares (+inf%) to their portfolio in Q2 2026, for an estimated $58,253,516
- FMR LLC added 2,054,127 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,329,035
- AFFINITY ASSET ADVISORS, LLC added 2,032,012 shares (+inf%) to their portfolio in Q2 2026, for an estimated $40,884,081
- BLACKROCK, INC. added 1,963,541 shares (+inf%) to their portfolio in Q2 2026, for an estimated $39,506,444
- TRAILS EDGE CAPITAL PARTNERS, LP added 1,514,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $30,461,680
- VESTAL POINT CAPITAL, LP added 1,013,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,381,560
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TRAX Price Targets
Multiple analysts have issued price targets for $TRAX recently. We have seen 7 analysts offer price targets for $TRAX in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $30.0 on 07/08/2026
- Derek Archila from Wells Fargo set a target price of $30.0 on 06/08/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $54.0 on 05/04/2026
- David Risinger from Leerink Partners set a target price of $46.0 on 04/24/2026
- Anupam Rama from JP Morgan set a target price of $31.0 on 04/23/2026
- Etzer Darout from Barclays set a target price of $40.0 on 04/22/2026
- Michael Yee from UBS set a target price of $45.0 on 04/21/2026
Full Release
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.
A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events . The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn .
Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
[email protected]